Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Intercept Pharma, and Ocular Therapeutix. According to TipRanks, Wolleben has an average return of -8.3% and a 35.56% success rate on recommended stocks.
Currently, the analyst consensus on Ocular Therapeutix is a Strong Buy with an average price target of $16.67.
Based on Ocular Therapeutix’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $12.27 million and a GAAP net loss of $18.77 million. In comparison, last year the company earned a revenue of $11.72 million and had a GAAP net loss of $8.48 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.